Business Wire

ThetaRay and Spayce Partner to Combat Financial Crime and Secure Global Payments with Cognitive AI

3.6.2025 06:00:00 CEST | Business Wire | Press Release

Share

ThetaRay, a global leader in Cognitive AI financial crime compliance, and Spayce, a cross-border payments platform, today announced a strategic partnership to combat evolving financial threats and enhance global payment security. The collaboration will be officially unveiled at Money 20/20.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250602138235/en/

The announcement comes at a time when the financial crime landscape is undergoing a dramatic transformation. As criminal networks grow more sophisticated and agile, operating with the complexity of multinational corporations, traditional rule-based anti-money laundering (AML) systems are increasingly outpaced. These outdated tools often miss hidden threats, allowing illicit activity to slip through undetected and exposing institutions to regulatory, financial, and reputational risk.

Spayce has deployed ThetaRay’s Cognitive AI Transaction Monitoring solution into its global payments infrastructure to enhance its financial crime detection capabilities. ThetaRay’s solution uses Cognitive AI to continuously analyze the vast volumes of transaction data, detecting nuanced suspicious activity, and uncovering complex financial crime schemes with exceptional accuracy. This AI-first approach not only strengthens compliance but empowers Spayce to scale securely, turning regulatory readiness into a foundation for sustainable growth.

Spayce, which serves clients ranging from SMBs to large financial institutions in over 200 countries, now gains deeper visibility into transaction flows without compromising speed or customer experience. The result is a smarter, faster, and more secure global payments ecosystem, one where compliance no longer slows expansion, but actively enables it.

“Financial crime is evolving rapidly, and the technology used to combat it must evolve even faster,” said Peter Reynolds, CEO of ThetaRay. “Our partnership with Spayce unites robust payment infrastructure with ThetaRay’s Cognitive AI to deliver proactive risk mitigation, greater transparency, and the trusted cross-border transactions needed to power global growth.”

“As Spayce expands its global payments capabilities, security and AML compliance remain at the core of our mission,” said Debra LePage, Partner & Co-Founder of Spayce. “Partnering with ThetaRay empowers us to stay ahead of increasingly sophisticated financial threats, while continuing to deliver seamless, trusted payment experiences for our customers worldwide.”

About ThetaRay
ThetaRay harnesses the power of Cognitive AI for financial crime compliance, enabling financial institutions to precisely identify legitimate customers while flagging bad actors. The SaaS solutions overcome the limitations of traditional rule-based systems by shortening long implementation lifecycles, enabling efficient, risk-aware compliance operations. By transforming compliance from a regulatory obligation into a driver of growth, ThetaRay allows institutions to scale faster and expand confidently into new markets. By uncovering hidden criminal networks and delivering actionable insights, ThetaRay empowers organizations to combat evolving threats, maintain positive regulator relationships, and enhance customer experiences. Implemented at some of the world’s leading financial institutions including Santander, Clear Bank, Mashreq Bank, Payoneer, Onafriq and Travelex, ThetaRay helps financial institutions thrive, fostering trust and confidence across the global financial ecosystem.

About Spayce
Spayce is a next-generation cross-border payment platform enabling seamless, secure, and scalable global transactions. With over three decades of experience in the payments and financial technology industry, Spayce is the trusted payments technology partner that businesses rely on to move their money securely and efficiently domestically and across borders.

Built by industry veterans, Spayce supports a wide range of use cases—including vendor payouts, global payroll, eCommerce settlements, and real-time B2P and B2B payments—through powerful APIs, a hosted checkout solution, and an intuitive merchant portal.

Through their trusted network of global banking partners, Spayce delivers speed, transparency, and compliance at scale; with a deep commitment to financial crime prevention and regulatory excellence, Spayce enables clients to grow globally with confidence while maintaining the highest standards of trust and security. Operating in over 200 countries and territories, Spayce combines cutting-edge technology with deep regulatory and operational expertise to deliver frictionless payment experiences.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250602138235/en/

Contacts

Media Contact: pr@thetaray.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye